10x Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only. Codename:Pepe is merging AI with memecoin culture, ...

10x Genomics (NASDAQ:TXG – Get Free Report) had its price target reduced by investment analysts at Citigroup from $20.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports.

Popcorn is one of my all-time favorite snacks, especially now that I have to eat gluten-free. It's a quick way to fill me up without having to worry about what's in it. Whether it's buttery movie ...

This month's cover highlights the article Nup358 restricts ER-mitochondria connectivity by modulating mTORC2/Akt/GSK3β signalling by Joseph, Misha Kalarikkal and colleagues. The image shows a human ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

Functional genomics uses genomic data to study gene and protein expression and function on a global scale (genome-wide or system-wide), focusing on gene transcription, translation and protein ...

"By transforming questions about metabolism into a genomics challenge, we were able to draw a 'wiring map' of adult worm metabolism that revealed numerous novel insights." "The most exciting part ...

It features a software stock we’re confident has 10X potential. Road sign showing a fork in the road Philip Panaro is the founder and former CEO of Boston Consulting Group who clearly remains ...

Assets in the region span medtech/medical device development and manufacturing, bioinformatics, genomics, nutrition, human health, clinical research, and, increasingly, biopharma manufacturers.

However, only $17.5 billion, less than half, represents genuine long-only buying, reported 10x Research head of research Markus Thielen. The majority, or around 56%, “is likely tied to arbitrage ...